recombinant human erythropoietin is a glycoprotein hormone that stimulates erythropoiesis. in clonogenic assays of hematopoietic progenitors, high concen-trations of erythropoietin (epo) increase cfu-e and diminish the number of granulocytes formed per culture plate. fetal progenitors are more sensitive to these effects of epo than progenitors from adults. we administered doses 50, 100, 200 iu/...

BACKGROUND It is known that the immunogenicity of hepatitis B virus (HBV) vaccine is lower in uremic patients than healthy subjects. Numerous inherited or acquired factors have been implicated in this lowered response, and the high frequency of recombinant human erythropoietin use among patients on maintenance dialysis has been suggested to play a pivotal role. However, the impact of therapy wi...

Recombinant human erythropoietin (EPO) is the main therapeutic glycoprotein for treatment of anemia in cancer and kidney patients. The in-vivo activity EPO carbohydrate-dependent with number sialic acid residues regulating its circulatory half-life. carries three N-glycans thus obtaining pure glycoforms provides a major challenge. We have developed robust reproducible chemoenzymatic approach to...